Table 1.
Demographics and baseline disease characteristicsa
| Ixekizumab (n = 520) | Guselkumab (n = 507) | |
|---|---|---|
| Age, years | 49·0 ± 13·9 | 49·0 ± 14·9 |
| Women, n (%) | 182 (35) | 193 (38) |
| White ethnicity, n (%) | 439 (85) | 431 (85) |
| Weight (kg) | 96·6 ± 24·9 | 94·6 ± 24·9 |
| ≥ 100 kg, n (%) | 197 (38) | 171 (34) |
| Body mass index (kg/m2) | 32·9 ± 7·9 | 32·8 ± 7·9 |
| Country, n (%) | ||
| Canada | 103 (20) | 106 (21) |
| U.S.A. | 417 (80) | 401 (79) |
| Years since diagnosis | 17·5 ± 13·8 | 16·3 ± 13·8 |
| PASI (range 0–72) | 19·5 ± 7·9 | 19·3 ± 7·1 |
| PASI (range 0–72), median (IQR) | 17·0 (7·7) | 17·4 (7·5) |
| sPGA score, n (%) | ||
| 3 | 266 (51) | 252 (50) |
| 4 | 224 (43) | 232 (46) |
| 5 | 29 (6) | 23 (5) |
| % Body surface area | 24·1 ± 16·1 | 23·8 ± 15·4 |
| DLQI | 12·8 ± 6·9 | 13·2 ± 7·4 |
| Skin pain VAS | 47·0 ± 29·9 | 47·2 ± 30·5 |
| Itch NRS | 6·9 ± 2·4 | 7·1 ± 2·5 |
| Previous therapy, n (%) | ||
| Nonbiologic systemic | 170 (33) | 140 (28) |
| Topical therapy | 373 (72) | 352 (69) |
| Phototherapy | 77 (15) | 63 (12) |
| Biologic | 137 (26) | 133 (26) |
| Number of prior biologics, n (%) | ||
| 1 | 95 (18) | 96 (19) |
| 2 | 28 (5) | 27 (5) |
| ≥ 3 | 14 (3) | 10 (2) |
| Prior biologic class, n (%) | ||
| Anti‐IL‐17 | 25 (5) | 29 (6) |
| Anti‐IL‐17 only | 11 (2) | 16 (3) |
| Anti‐IL‐12/IL‐23 only | 11 (2) | 14 (3) |
| Anti‐TNF only | 84 (16) | 67 (13) |
| Other | 2 (0·4) | 10 (2) |
| Multiple | 29 (6) | 26 (5) |
| Prior biologic failures, n (%) | 41 (8) | 36 (7) |
Data are mean ± SD, unless otherwise indicated. PASI, Psoriasis Area and Severity Index; sPGA, static Physician's Global Assessment; DLQI, Dermatology Life Quality Index; VAS, visual analogue scale; NRS, numeric rating scale; IL, interleukin; TNF, tumour necrosis factor‐alpha; aPercentages were calculated based on the number of patients with nonmissing values.